GATA6-upregulating autophagy promotes TKI resistance in nonsmall cell lung cancer. Issue 9 (2nd September 2019)

• Record Type: Journal Article
• Authors: Ma, Ruishuang; Li, Xin; Liu, Huan; Jiang, Rui; Yang, Maopeng; Zhang, Minghui; Wang, Yan; Zhao, Yanbin; Li, Hulun
• Is Part Of: Cancer biology & therapy. Volume 20:Issue 9(2019)
• Page Start: 1206
• Page End: 1212
• Publication Date: 2019-09-02
• Subjects: Non-small cell lung cancer -- GATA6 -- autophagy -- TKI resistance -- Exon 19 deletions; 616.99406
• DOI: 10.1080/15384047.2019.1599665
• Languages: English
• ISSNs: 1538-4047

Abstract

ABSTRACT: Autophagy plays a complicated role in tumorigenesis, and the effects of autophagy in drug resistance have not been fully known. The aim of this study was to evaluate autophagy activity in lung cancer cells derived from different origins and explore the mechanism regulating autophagy in tyrosine kinase inhibitor (TKI) resistance. We found basal level of autophagy had no significant increase in resistant H1650 and H1975 cells compared with sensitive HCC827 and PC9 cells. After erlotinib treatment, the autophagy activity enhanced threefold in H1650 cells but a little in H1975 cells. Inhibiting autophagy with 3-MA increased apoptosis in H1650 rather than H1975 cells. Combined with transmission microscope, results showed PC9 cells tended to be apoptotic and more autophagosomes formed in H1650 cells, which may be correlated with cell viability. GATA6 expression was found markedly elevated in H1650 cells after erlotinib and knocking down GATA6 led to significantly reduced autophagy activity and cell viability. Furthermore, a significant increase of GATA6 and LC3-II expression was observed in insensitive tissues compared with sensitive ones by immunostaining in nonsmall cell lung cancer (NSCLC) patients. With chi-square test, we found GATA6 was positively correlated with LC3-II. The Kaplan-Meier curve analyses further showed patients with high GATA6 had lower overall survival and progression-free survival rates than those with low GATA6 after EGFR-TKI treatment. Our results suggest that GATA6 could enhance autophagy activity contributing to TKI resistance. Targeting GATA6 and autophagy together with TKI may be promising to overcome drug resistance in NSCLC.